Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Harvard Business School
Dow
AstraZeneca
McKinsey

Last Updated: February 4, 2023

Details for Patent: 7,491,725


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,491,725 protect, and when does it expire?

Patent 7,491,725 protects SPRYCEL and is included in one NDA.

Protection for SPRYCEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-seven patent family members in twenty-nine countries.

Summary for Patent: 7,491,725
Title:Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Abstract:The invention relates to processes for preparing compounds having the formula, ##STR00001## and crystalline forms thereof, wherein Ar is aryl or heteroaryl, L is an optional alkylene linker, and R.sub.2, R.sub.3, R.sub.4, and R.sub.5, are as defined in the specification herein, which compounds are useful as kinase inhibitors, in particular, inhibitors of protein tyrosine kinase and p38 kinase.
Inventor(s): Lajeunesse; Jean (Candiac, CA), DiMarco; John D. (East Brunswick, NJ), Galella; Michael (Kendall Park, NJ), Chidambaram; Ramakrishnan (Pennington, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:11/192,867
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,491,725
Patent Claim Types:
see list of patent claims
Compound; Composition; Process;

Drugs Protected by US Patent 7,491,725

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-001 Jun 28, 2006 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-002 Jun 28, 2006 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-003 Jun 28, 2006 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-005 Oct 28, 2010 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
AstraZeneca
Mallinckrodt
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.